OXAliplatin - Latest Advances

Patient and Clinician Views on Risk Prediction for Chemotherapy-Induced Peripheral Neuropathy.

Journal: Journal of pain & palliative care pharmacotherapy

Published: October 17, 2025

Chemotherapy and Supportive Care Practice Patterns Among Older Adults With Metastatic Pancreatic Cancer.

Journal: JCO oncology practice

Published: October 16, 2025

RETRACTION: LncRNA NR2F1-AS1 Regulates Hepatocellular Carcinoma Oxaliplatin Resistance by Targeting ABCC1 via miR-363.

Journal: Journal of cellular and molecular medicine

Published: October 15, 2025

Association of Plasma Creatinine with Systemic Exposure to S-1 and Oxaliplatin in Two Types of Chronic Kidney Disease Animal Models.

Journal: Biological & pharmaceutical bulletin

Published: October 13, 2025

MINING THE CELLMINER DATABASE TO IDENTIFY SHARED BIOMARKERS OF 5-FU AND OXALIPLATIN RESPONSE.

Journal: Georgian medical news

Published: October 10, 2025

TGFB1-mediated autophagy facilitates oxaliplatin resistance in stomach adenocarcinoma.

Journal: Biochemistry and cell biology = Biochimie et biologie cellulaire

Published: October 07, 2025

Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 Quantification and Clinical Outcomes in Human Epidermal Growth Factor Receptor 2-Positive Biliary Tract Cancer Treated With Trastuzumab Plus Folinic Acid, Fluorouracil, and Oxaliplatin.

Journal: JCO precision oncology

Published: October 02, 2025

Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 02, 2025

Erratum: Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 02, 2025

The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical Trials.

Journal: JAMA oncology

Published: October 02, 2025

Complex Ocular Adverse Events Following Oxaliplatin Treatment: A Case Report.

Journal: The American journal of case reports

Published: September 29, 2025

Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 29, 2025

Filters

Patient and Clinician Views on Risk Prediction for Chemotherapy-Induced Peripheral Neuropathy.

Patient and Clinician Views on Risk Prediction for Chemotherapy-Induced Peripheral Neuropathy.

Chemotherapy and Supportive Care Practice Patterns Among Older Adults With Metastatic Pancreatic Cancer.

Chemotherapy and Supportive Care Practice Patterns Among Older Adults With Metastatic Pancreatic Cancer.

RETRACTION: LncRNA NR2F1-AS1 Regulates Hepatocellular Carcinoma Oxaliplatin Resistance by Targeting ABCC1 via miR-363.

RETRACTION: LncRNA NR2F1-AS1 Regulates Hepatocellular Carcinoma Oxaliplatin Resistance by Targeting ABCC1 via miR-363.

Association of Plasma Creatinine with Systemic Exposure to S-1 and Oxaliplatin in Two Types of Chronic Kidney Disease Animal Models.

Association of Plasma Creatinine with Systemic Exposure to S-1 and Oxaliplatin in Two Types of Chronic Kidney Disease Animal Models.

MINING THE CELLMINER DATABASE TO IDENTIFY SHARED BIOMARKERS OF 5-FU AND OXALIPLATIN RESPONSE.

MINING THE CELLMINER DATABASE TO IDENTIFY SHARED BIOMARKERS OF 5-FU AND OXALIPLATIN RESPONSE.

TGFB1-mediated autophagy facilitates oxaliplatin resistance in stomach adenocarcinoma.

TGFB1-mediated autophagy facilitates oxaliplatin resistance in stomach adenocarcinoma.

Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 Quantification and Clinical Outcomes in Human Epidermal Growth Factor Receptor 2-Positive Biliary Tract Cancer Treated With Trastuzumab Plus Folinic Acid, Fluorouracil, and Oxaliplatin.

Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 Quantification and Clinical Outcomes in Human Epidermal Growth Factor Receptor 2-Positive Biliary Tract Cancer Treated With Trastuzumab Plus Folinic Acid, Fluorouracil, and Oxaliplatin.

Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial.

Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial.

Erratum: Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.

Erratum: Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.

The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical Trials.

The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical Trials.

Complex Ocular Adverse Events Following Oxaliplatin Treatment: A Case Report.

Complex Ocular Adverse Events Following Oxaliplatin Treatment: A Case Report.

Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis.

Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis.